Singapore, March 6 -- Taiwan-based Health2Sync, a leading digital health company specialising in chronic disease management, has raised over $20 million in a Series C funding round and earlier extension round. This investment will propel the company's growth initiatives, including expansion into new markets, development of innovative programs, and preparations for a public listing in Taiwan.

The funding round was led by Taiwania Capital, with participation from prominent investors, including Wistron, Pegatron, BE Health Ventures, ABIES Capital, and Cathay Venture. The strong support from new and existing investors underscores confidence in Health2Sync's vision and track record of what it has developed as Asia's largest chronic disease ma...